H
Hitoshi Matsuo
Researcher at Hitachi
Publications - 239
Citations - 6139
Hitoshi Matsuo is an academic researcher from Hitachi. The author has contributed to research in topics: Fractional flow reserve & Coronary artery disease. The author has an hindex of 36, co-authored 238 publications receiving 5009 citations. Previous affiliations of Hitoshi Matsuo include Saitama University.
Papers
More filters
Journal ArticleDOI
Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI
Justin E. Davies,Sayan Sen,Hakim-Moulay Dehbi,Hakim-Moulay Dehbi,Hakim-Moulay Dehbi,Rasha Al-Lamee,Ricardo Petraco,Sukhjinder Nijjer,Ravinay Bhindi,Sam J. Lehman,Darren L. Walters,James Sapontis,Luc Janssens,Christiaan J. Vrints,Ahmed Khashaba,Mika Laine,E. Van Belle,Florian Krackhardt,Waldemar Bojara,Olaf Going,Tobias Härle,Ciro Indolfi,Giampaolo Niccoli,Flavo Ribichini,Nobuhiro Tanaka,Hiroyoshi Yokoi,Hiroaki Takashima,Yuetsu Kikuta,Andrejs Erglis,Hugo Vinhas,P. Canas Silva,Sérgio Bravo Baptista,Ali Alghamdi,Farrel Hellig,Bon Kwon Koo,Chang Wook Nam,Eun-Seok Shin,Joon Hyung Doh,Salvatore Brugaletta,Eduardo Alegría-Barrero,Martijn Meuwissen,Jan J. Piek,N. van Royen,Murat Sezer,C. Di Mario,Robert Gerber,Iqbal S. Malik,Andrew S.P. Sharp,Suneel Talwar,Kare Tang,Habib Samady,John D. Altman,Arnold H. Seto,J. Singh,Allen Jeremias,Hitoshi Matsuo,Rajesh K. Kharbanda,Manesh R. Patel,P. Serruys,Javier Escaned,Javier Escaned +60 more
TL;DR: Coronary revascularization guided by iFR was noninferior to revascularizations guided by FFR with respect to the risk of major adverse cardiac events at 1 year.
Journal ArticleDOI
Procedural and In-Hospital Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusions of Coronary Arteries 2002 to 2008: Impact of Novel Guidewire Techniques
Sudhir Rathore,Hitoshi Matsuo,Mitsuyasu Terashima,Yoshihisa Kinoshita,Masashi Kimura,Etsuo Tsuchikane,Kenya Nasu,Mariko Ehara,Yasushi Asakura,Osamu Katoh,Takahiko Suzuki +10 more
TL;DR: This is the first reported large series of patients undergoing PCI for chronic total occlusion with improved wire crossing techniques and identified severe tortuosity and moderate-to-severe calcification as significant predictors of procedural failure.
Journal ArticleDOI
Retrograde Percutaneous Recanalization of Chronic Total Occlusion of the Coronary Arteries Procedural Outcomes and Predictors of Success in Contemporary Practice
Sudhir Rathore,Osamu Katoh,Hitoshi Matsuo,Mitsuyasu Terashima,Nobuyoshi Tanaka,Yoshihisa Kinoshita,Masashi Kimura,Etsuo Tsuchikane,Kenya Nasu,Mariko Ehara,Keiko Asakura,Yasushi Asakura,Takahiko Suzuki +12 more
TL;DR: The retrograde approach in CTO percutaneous coronary intervention is effective in recanalizing CTO with acceptable overall adverse events and predictors of failure related to collateral morphology are identified.
Journal ArticleDOI
Mitochondrial Haplogroup N9a Confers Resistance against Type 2 Diabetes in Asians
Noriyuki Fuku,Kyong Soo Park,Yoshiji Yamada,Yutaka Nishigaki,Young Min Cho,Hitoshi Matsuo,Tomonori Segawa,Sachiro Watanabe,Kimihiko Kato,Kiyoshi Yokoi,Yoshinori Nozawa,Hong Kyu Lee,Masashi Tanaka +12 more
TL;DR: Multivariate logistic-regression analysis with adjustment for age and sex revealed that the mitochondrial haplogroup N9a was significantly associated with resistance against type 2 diabetes mellitus (T2DM), suggesting that even in the modern environment, which is often characterized by satiety and physical inactivity, this haplogroups might confer resistance against T2DM.
Journal Article
Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG.
Hisato Takatsu,Hiroshi Nishida,Hitoshi Matsuo,Sachiro Watanabe,Kenshi Nagashima,Hisayasu Wada,Toshiyuki Noda,Kazuhiko Nishigaki,Hisayoshi Fujiwara +8 more
TL;DR: Cardiac scintigraphy with 123I-MIBG may be used as a new imaging approach in the diagnosis and characterization of akinetic-rigid syndromes, especially Parkinson's disease, and indicated that the postganglionic sympathetic nerves may be damaged by MPTP or unknown toxic substrates in experimental or human Parkinson's Disease during the early stage.